indications for semaglutide vs GLP-1: Key Differences Explained fda approved indications for semaglutide

Summary Keywords glaucoma, GLP-1 receptor agonists, antidiabtics, ophthalmology, neuroprotection, neurodegenerative diseases Citation Mouhammad ZA, Vohra R, Horwitz A, Thein A-S, Rovelt J, Cvenkel B, Williams PA, Azuara-Blanco A and Kolko M (2022) Glucagon-Like Peptide 1 Receptor Agonists Potential Game Changers in the Treatment of Glaucoma

Emerging research suggests that allulose may stimulate GLP-1 secretion, though the mechanisms remain hypothetical

Tirzepatide A dual-acting medication that targets both GLP-1 and GIP receptors, offering an advanced approach to weight control and blood sugar management

Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges